GT Biopharma, Inc.
GTBP
$0.42
-$0.01-1.69%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
6/8/2026
-
Globe Newswire
6/2/2026
-
CNW Group - News Releases
6/2/2026
-
PR Newswire
6/1/2026
-
Globe Newswire
6/1/2026
-
Benzinga
5/29/2026
-
The Cerbat Gem
5/29/2026
-
CNW Group - News Releases
5/29/2026
-
PR Newswire
5/19/2026
-
CNW Group - News Releases
5/19/2026
-
PR Newswire
5/18/2026
-
PR Newswire
5/18/2026
-
CNW Group - News Releases
5/16/2026
-
The Cerbat Gem
5/15/2026
-
Globe Newswire
5/14/2026
-
Globe Newswire
5/14/2026
-
Globe Newswire
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
5/14/2026
-
CNW Group - News Releases
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
5/14/2026
-
PR Newswire
5/14/2026
-
Benzinga
4/30/2026
-
TipRanks Financial Blog
4/30/2026
-
The Fly
3/20/2026
-
TipRanks Financial Blog
3/16/2026
-
Zacks Investment Research
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, May 15, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
415 919 4040
Address
315 Montgomery Street
San Francisco, CA 94104
San Francisco, CA 94104
Country
Year Founded
Business Description
Sector
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and...
more